Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Immunic, Inc. (IMUX : NSDQ)
 
 • Company Description   
Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis and psoriasis. The company's product candidate consists of IMU-838, IMU-935 and IMU-856 which are in clinical stage. Immunic Inc., formerly known as Vital Therapies Inc., is based in San Diego, United States.

Number of Employees: 55

 
 • Price / Volume Information   
Yesterday's Closing Price: $5.77 Daily Weekly Monthly
20 Day Moving Average: 346,261 shares
Shares Outstanding: 30.54 (millions)
Market Capitalization: $176.22 (millions)
Beta: 1.99
52 Week High: $15.12
52 Week Low: $4.96
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -29.03% -20.07%
12 Week -46.18% -40.83%
Year To Date -39.71% -30.03%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1200 AVENUE SUITE 200
-
NEW YORK,NY 10036
USA
ph: 332-255-9818
fax: 858-673-6843
jessica.breu@immunic.de http://www.immunic-therapeutics.com
 
 • General Corporate Information   
Officers
Daniel Vitt - President;Chief Executive Officer;Director
Duane D. Nash - Executive Chairman
Glenn Whaley - Principal Financial and Accounting Officer
Tamar Howson - Director
Joerg Neermann - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 4525EP101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/05/22
Share - Related Items
Shares Outstanding: 30.54
Most Recent Split Date: 4.00 (0.03:1)
Beta: 1.99
Market Capitalization: $176.22 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.72 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.01 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.28
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 54.60%
vs. Previous Quarter: 8.64%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -59.64
12/31/21 - -70.05
09/30/21 - -58.97
ROA
03/31/22 - -54.46
12/31/21 - -63.38
09/30/21 - -53.90
Current Ratio
03/31/22 - 10.11
12/31/21 - 9.21
09/30/21 - 11.57
Quick Ratio
03/31/22 - 10.11
12/31/21 - 9.21
09/30/21 - 11.57
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 4.52
12/31/21 - 4.84
09/30/21 - 5.54
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©